Market Cap
$1.2B
MNKD
MANNKIND CORP
$3.74 ▼ -5.32%
Prev close $3.95Market cap$1.2B
ConsensusStrong Buy
12-mo target$7.97 (+113.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MNKD right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$621.0M
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $791.3K sell
Insider Net $
-$791.3K
Social Sentiment
80° Bullish
SEC Reports
8
Press Releases
5
Price chart 30d -7.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: MNKD — 60.9% short (2.5M / 4.1M)
Short: 2,473,048 | Exempt: 7,973 | TRF Vol: 4,058,716 | Short Ratio: 60.9% | Off-exchange volume (da
Sep 25, 2026 Insider
Binder Steven B. sold 39,051 shares
Director @ $3.29 ($128.5K)
Sep 10, 2026 Insider
Binder Steven B. sold 33,558 shares
Director @ $3.81 ($127.9K)
Aug 7, 2026 Insider
Jul 29, 2026 Press Binder Steven B. sold 39,051 shares
Director @ $4.06 ($158.5K)
MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (M
Impact 6/10
MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warrants at $3.88/share,
8-K — Impact 6/10
Two insiders at MannKind Corp — the EVP General Counsel and a Director — sold a combined $311K in open-market shares on
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
Rubric Capital Management LP — DOUBLED
18,000,000 shares ($76.7M)
Analyst ratings buy % -7.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 11, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Aug 6, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 30, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| May 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 28, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jun 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Price targets
Where 8 covering analysts think MNKD trades over the next 12 months.
$7.97 +113.1% upside Strong Buy
Current$3.74 Low$4.75 Median$7.50 High$13.00 8 analysts
$4.75$13.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
80°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 3 bullish, 1 bearish, 1 mixed, 3 neutral · avg impact 5.5/10.Plus 5 press releases.
MIXED8-K6/10
MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warr
Jul 24, 2026
NEUTRALCLUSTER3/10
Two insiders at MannKind Corp — the EVP General Counsel and a Director — sold a combined $311K in op
Jul 18, 2026
BULLISH8-K7/10
MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in ch
Jun 2, 2026
BULLISH8-K6/10
MannKind announced the FDA released it from a postmarketing requirement for Afrezza—a five-year pulm
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: MNKD — 60.9% short (2.5M / 4.1M)
Short: 2,473,048 | Exempt: 7,973 | TRF Vol: 4,058,716 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: MNKD — 65.5% short (0.7M / 1.1M)
Short: 748,956 | Exempt: 1,770 | TRF Vol: 1,143,841 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: MNKD — 60.1% short (0.5M / 0.9M)
Short: 542,575 | Exempt: 224 | TRF Vol: 902,933 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: MNKD — 64.5% short (0.9M / 1.4M)
Short: 924,354 | Exempt: 10,887 | TRF Vol: 1,432,623 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: MNKD — 60.1% short (0.6M / 1.0M)
Short: 593,031 | Exempt: 1,905 | TRF Vol: 985,990 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.01 | $-0.04–$0.01 | -107.1% | +0.0% | — | $0.1B | 4 |
| Next Q | $0.06 | $0.03–$0.11 | 525.0% | +0.0% | 1↑ 0↓ | $0.1B | 4 |
| Current FY | $0.03 | $0.01–$0.04 | -84.2% | +0.0% | — | $0.4B | 4 |
| Next FY | $0.13 | $0.05–$0.20 | 325.0% | +0.0% | 0↑ 1↓ | $0.5B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.005 | — |
| 7d ago | $-0.005 | — |
| 30d ago | $-0.005 | — |
| 60d ago | $0.020 | -0.025 |
| 90d ago | $0.020 | -0.025 |
Institutional ownership
Which big funds own MNKD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $621.0M total value (145,767,239 shares) as of 2026-Q2. Top holders: BlackRock,, Rubric, STATE. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 32,133,223 | $136.9M | 22.0% | — |
| Rubric Capital Management LP | 18,000,000 | $76.7M | 12.3% | DOUBLED +397.2% |
| STATE STREET CORP | 16,174,043 | $68.9M | 11.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 13,169,392 | $56.1M | 9.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 7,947,203 | $33.9M | 5.5% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 7,844,807 | $33.4M | 5.4% | DOUBLED +138.9% |
| FMR LLC | 4,101,046 | $17.5M | 2.8% | — |
| AQR CAPITAL MANAGEMENT LLC | 3,808,824 | $16.2M | 2.6% | — |
| MORGAN STANLEY | 3,474,870 | $14.8M | 2.4% | TRIM -40.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,002,169 | $12.8M | 2.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Rubric Capital Management LP | DOUBLED | 3,620,413 | 18,000,000 | +397.2% | $76.7M |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 3,283,179 | 7,844,807 | +138.9% | $33.4M |
| MORGAN STANLEY | TRIM | 5,793,147 | 3,474,870 | -40.0% | $14.8M |
| UBS Group AG | TRIM | 8,255,430 | 2,886,231 | -65.0% | $12.3M |
| BANK OF AMERICA CORP /DE/ | TRIM | 3,383,677 | 2,364,872 | -30.1% | $10.1M |
| GOLDMAN SACHS GROUP INC | TRIM | 2,942,320 | 2,154,499 | -26.8% | $9.2M |
| WELLS FARGO & COMPANY/MN | ADD | 860,474 | 1,476,413 | +71.6% | $6.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 715,862 | 1,180,803 | +64.9% | $5.0M |
| DIMENSIONAL FUND ADVISORS LP | NEAR_EXIT | 4,953,295 | 1,094,192 | -77.9% | $4.7M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 206,513 | 684,107 | +231.3% | $2.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$791.3K — $0.00 bought, $791.3K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Binder Steven B. | Director | SELL | 39,051 | $3.29 | $128.5K |
| Sep 10, 2026 | Binder Steven B. | Director | SELL | 33,558 | $3.81 | $127.9K |
| Aug 7, 2026 | Binder Steven B. | Director | SELL | 39,051 | $4.06 | $158.5K |
| Jul 17, 2026 | Binder Steven B. | Director | SELL | 52,485 | $4.06 | $213.1K |
| Jul 17, 2026 | Thomson David | EVP Genl Counsel & Secretary | SELL | 24,109 | $4.05 | $97.6K |
| Jul 15, 2026 | Binder Steven B. | Director | EXERCISE | 93,790 | — | — |
| Jul 15, 2026 | Binder Steven B. | Director | TAX W/H | 15,688 | $4.09 | $64.2K |
| Jul 15, 2026 | Binder Steven B. | Director | TAX W/H | 4,073 | $4.09 | $16.7K |
| Jul 15, 2026 | Thomson David | EVP Genl Counsel & Secretary | EXERCISE | 93,790 | — | — |
| Jul 15, 2026 | Thomson David | EVP Genl Counsel & Secretary | TAX W/H | 16,378 | $4.09 | $67.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MNKD.
Shares short
29,398,550
Settlement Sep 15, 2026
Change vs prior
+10.7%
Semi-monthly cycle
Days to cover
9.1
At avg daily volume
Of shares outstanding
≈9.1%
Estimate — not % of float
All MNKD filing & press-release reports (13)
- PRESS-RELEASE reportJul 29, 2026
- 8-K reportJul 24, 2026
- CLUSTER reportJul 18, 2026
- PRESS-RELEASE reportJun 3, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 29, 2026
- PRESS-RELEASE reportMay 29, 2026
- 8-K reportMay 28, 2026
- PRESS-RELEASE reportMay 27, 2026
- CLUSTER reportMay 14, 2026
- PRESS-RELEASE reportMay 6, 2026
- DEFA14A reportApr 7, 2026
- 8-K reportFeb 26, 2026